The Quanterix SP-X™ Imaging and Analysis System is a complete benchtop system that provides accurate multiplex identification for acute and basal levels in serum and plasma.
Now, oncology and immuno-oncology researchers, along with others who rely on multiplexing capabilities, have access to an easy-to-use platform. This platform helps streamline workflows, accelerate research, and ultimately accelerate drug approvals.
Simoa® planar chemiluminescent arrays provide state-of-the-art accuracy, precision, sensitivity and reproducibility.
Image credit: Quanterix
Unique SP-X™ Capabilities
- Easy-to-use and flexible data analysis software
- An open platform for ultra-sensitive personalization
- Assay development
- Combining Simoa ultra-sensitivity with 10-plex
- Multiplexing
- Compact instrument footprint, requiring only
- 11” (28 cm) of counter space
- Integrated high-resolution camera and custom lens for
- Optimal light collection without user adjustments
- Optimized image analysis with proprietary acquisition
- Algorithms and machine learning maximize momentum
- Range and S/N
- Touchscreen tablet interface
- 21CFR Part 11 Compliant Workflow
- Imaging time in less than 10 minutes
- Low maintenance
State-of-the-art imaging and data analysis
Multiplex measurement of normal and healthy basal levels using the Simoa CorPlex® Panel 1 of human cytokines in the SP-X system. Image credit: Quanterix
SP-X™ integrated data intelligence program
1. Calibrator/sample dilution import and configuration panel. Image credit: Quanterix
2. Build a plate map or load it from an Excel file. Image credit: Quanterix
3. Open a .kit file. Image credit: Quanterix
4. Click on “Process Kit”. Image credit: Quanterix
5. Review the data and results report. Image credit: Quanterix
Simoa SP-X™ workflow: simple, scalable, flexible
1. Add reagents and samples to the assay plate. Image credit: Quanterix
2. Incubate and shake the assay plate. Image credit: Quanterix
3. Automated assay plate washing. Image credit: Quanterix
4. Load the assay plate into the SP-X™ for fast imaging. Image credit: Quanterix
How SP-X™ achieves ultrasensitivity
Simoa® planar immunoassay technology is an innovative digital biomarker solution. The unique features provide a simple, robust, flexible and sensitive multiplexing platform for researchers.
SP-X™ is a proprietary, precise digital nanofluidic antibody deposition technology. It provides unparalleled surface chemistry optimization, which minimizes non-specific binding and reduces low background noise. The precision and accuracy of the tests are exceptional.
Unique dot design antibodies are placed in individual dots in a circular pattern on the outside of each round well of the microtiter plate. Each spot contains the capture antibody for a target analyte.
With ten exclusive points in a single well, it is possible to carry out a total of 10 complex tests. This saves sample volume, cost, and time without losing assay performance attributes.
Vortex interaction between analyte molecules and capture antibodies.
The Simoa planar approach utilizes capture antibodies arranged in a circular pattern along with vortex mixing fluid dynamics. This combination maximizes sensitivity by promoting binding reactions to reach equilibrium and prevents the formation of depletion regions in the center of the well.
The Simoa surface of the planar array plates is manufactured from translucent materials, allowing imaging of the array through the bottom of the plate. This design eliminates the possibility of optical signal distortions and reduces sensitivity issues caused by the liquid meniscus in the wellbore.
Proprietary algorithm to calculate optimal exposure times for each individual plate.
Our proprietary algorithm allows SP-X™ Imager to automatically adjust exposure time and number of images. This optimization maximizes sensitivity and dynamic range for each experiment, ensuring optimal results.
About Quanterix
From discovery to diagnosis, Quanterix’s ultrasensitive biomarker detection is fueling advances made possible by its unmatched sensitivity and flexibility. Quanterix’s Simoa® technology has provided the gold standard for early detection of biomarkers in blood, serum or plasma, with the ability to quantify proteins that are well below the Limit of Quantification (LoQ) of conventional analog methods.
Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances the understanding and management of diseases in neurology, oncology, immunology, cardiology and infectious diseases. Quanterix has been a trusted partner to the scientific community for nearly two decades, powering research published in more than 2,500 peer-reviewed journals.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing business relationships, provided that such content adds value to the core editorial ethos of News-Medical.Net, which is to educate and inform interested site visitors in medicine research, science, medical devices and treatments.
